PT - JOURNAL ARTICLE AU - M. O. Nicoletto AU - S. Tumolo AU - R. Sorio AU - G. Cima AU - L. Endrizzi AU - O. Nascimben AU - O. Vinante AU - G. Artioli AU - M. Donach AU - G. Cartei TI - Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer AID - 10.1111/j.1525-1438.2007.00862.x DP - 2007 Sep 01 TA - International Journal of Gynecologic Cancer PG - 986--992 VI - 17 IP - 5 4099 - http://ijgc.bmj.com/content/17/5/986.short 4100 - http://ijgc.bmj.com/content/17/5/986.full SO - Int J Gynecol Cancer2007 Sep 01; 17 AB - The purpose of this study was to compare long-term survival in first-line chemotherapy with and without platinum in advanced-stage ovarian cancer. From July 1987 to November 1992, 161 untreated patients with FIGO stage III–IV epithelial ovarian cancer were randomized: 81 patients received no platinum and 80 received platinum combination. Residual disease after surgery was <2 cm in 61 patients without platinum, 59 with platinum. Median age was 58 years in nonplatinum arm and 55 years in platinum arm (range: 15–73). Complete and partial responses were 51% and 10% for nonplatinum arm and 51% and 8% for platinum arm, respectively (P= 0.7960). Stable disease was observed in 18% of patients in nonplatinum arm and 15% of patients in platinum arm and progression in 20% of nonplatinum- and 21% of platinum-treated cases. Ten-year disease-free survival was 37% for therapy without platinum and 31% for platinum combination (P= 0.5679); 10-year overall survival was 23% without platinum and 31% with platinum combination (P= 0.2545). Fifteen-year overall survival showed a trend of short duration in favor of platinum (P= 0.0678). Relapses occurred after 60 months in ten patients (seven with and three without platinum). The overall and disease-free survivals at 5, 10, and 15 years show no statistically significant long-term advantage from the addition of cisplatin; however, there is a slight trend in its favor.